1. Show article details.

    Johnson & Johnson Announces Completion of Cordis Divestiture to Cardinal Health

    PR Newswire – 7:00 PM ET 10/04/2015

    NEW BRUNSWICK, N.J., Oct. 4, 2015  Johnson & Johnson (JNJ) today announced the completion of the divestiture of its Cordis (JNJ) business to Cardinal Health for an approximate value of $2 billion, subject to customary adjustments. The Cordis (JNJ) business is a global leader in the development and manufacture of interventional vascular technology and generated net revenues of approximately $780 million in 2014.

  2. Show article details.

    Johnson & Johnson's stock paces Dow gainers after analyst upgrade

    MarketWatch – 1:51 PM ET 09/29/2015

    Johnson& Johnson's stock climbed 2% in afternoon trade Tuesday, making it the biggest percentage gainer among Dow Jones Industrial Average components, after the drug and consumer products company was upgraded at Deutsche Bank, which said concerns about the outlook for its pharmaceutical business are overdone. Analyst Kristen Stewart raised her rating to buy, after being at hold since July 17, 2013, while maintaining her stock price target at $110, which is 18% above current...

  3. Johnson & Johnson upgraded to buy from hold at Deutsche Bank

    MarketWatch – 1:06 PM ET 09/29/2015
  4. Johnson & Johnson finishes up 0.4%

    MarketWatch – 4:02 PM ET 09/28/2015
  5. Johnson & Johnson sole Dow component in positive territory at close

    MarketWatch – 4:02 PM ET 09/28/2015
  6. Show article details.

    Hip implant maker claims surgical funder inflated patients' bills

    Reuters – 1:00 AM ET 09/28/2015

    A unit of Johnson & Johnson (JNJ) that makes artificial hips has accused a surgical funding company of seeking excessive profits from financing surgery for patients suing over the devices.

  7. Show article details.

    Johnson & Johnson Consumer Inc. Announces Completion of the Divestiture of SPLENDA® Brand to Heartland Food Products Group

    PR Newswire – 4:15 PM ET 09/25/2015

    SKILLMAN, N.J., Sept. 25, 2015   Johnson & Johnson Consumer Inc. today announced it has completed the divestiture of the SPLENDA® brand to Heartland Food Products Group. About Johnson & Johnson Consumer Inc. Johnson & Johnson Consumer Inc., based in Skillman, N.J., is the world's sixth-largest consumer health and personal care products company.

  8. Show article details.

    BRIEF-EMA committee accelerates assessment of Genmab's daratumumab

    Reuters – 5:21 AM ET 09/25/2015

    Genmab A/S (GNMSF). * Says the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted accelerated assessment to the Marketing Authorization Application for daratumumab. * The MAA is for daratumumab as a treatment for patients with relapsed and refractory multiple myeloma.

  9. Show article details.

    Major companies join alliance seeking 100 pct green electricity

    Reuters – 9:06 AM ET 09/23/2015

    Companies including Goldman Sachs, Walmart and Starbucks (SBUX) joined an alliance on Wednesday that aims to get 100 percent of electricity from renewable sources to combat climate change. The green electricity campaign, RE100, said its membership had expanded to 36 companies from 12 at a launch a year ago in New York that included IKEA Group, Swiss RE and BT Group.

  10. Show article details.

    Technical Data on Healthcare Stocks - Infinity Pharmaceuticals, Boston Scientific, Johnson & Johnson, Mallinckrodt and Eli Lilly

    PR Newswire – 8:45 AM ET 09/22/2015

    NEW YORK, September 22, 2015 ACI Association has initiated research coverage on the following equities: Infinity Pharmaceuticals (INFI), Inc.  , Boston Scientific Corporation (BSX), Johnson & Johnson (JNJ), Mallinckrodt plc, Eli Lilly and Company.

  11. Show article details.

    For working mothers flextime, childcare, paid leave are key issues

    Reuters – 7:00 AM ET 09/22/2015

    Flextime, childcare options and paid maternity leave are the keys issues for working mothers in the United States and what set companies apart as the best places to work, employment experts said on Tuesday.

  12. Merck closes down 2.2%; Pfizer ends off 1.3%

    MarketWatch – 4:08 PM ET 09/21/2015
  13. Health-care related names pace Dow laggards

    MarketWatch – 4:08 PM ET 09/21/2015
  14. Show article details.

    Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

    PR Newswire – 6:13 PM ET 09/15/2015

    NEW BRUNSWICK, N.J., Sept. 15, 2015  Johnson & Johnson (JNJ) will host a conference call for investors at 8:30 a.m. on Tuesday, Oct. 13th, to review third-quarter results. Investors and other interested parties can access the webcast/conference call in the following ways: About Johnson & Johnson Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson.

  15. Show article details.

    DepoMed Urges Holders to Reject Horizon Offer

    DJ Business News – 10:05 AM ET 09/14/2015

    DepoMed Inc. (DEPO) said its board urged its shareholders to reject Horizon Pharma PLC's (HZNP) unsolicited bid to acquire the company in a share-exchange offer, reiterating that the deal significantly undervalues the company. Depomed (DEPO) holders have been offered 0.95 Horizon share for each Depomed (DEPO) share held, an offer valued at roughly $27.54 a share as of Friday's close. Horizon first made an all-stock offer to buy Depomed (DEPO) in a letter sent May 27, and then went public with an increased...

  16. Visa, Johnson & Johnson down 0.7% to lead Dow decliners

    MarketWatch – 9:40 AM ET 09/11/2015
  17. Show article details.

    The numbers don't lie: Apple's stock is a bargain

    MarketWatch – 4:50 PM ET 09/10/2015

    Even as the world's largest company, Apple (AAPL) keeps outperforming. In late July, I said investors were looking at a "golden opportunity to buy Apple's (AAPL) stock" after the iPhone maker's shares declined 4%. That drop followed a fiscal third-quarter earnings report that showed strong earnings and sales growth, but the company disappointed investors with a lower-than-expected outlook for fourth-quarter sales.

  18. Show article details.

    BRIEF-Genmab announces European regulatory submission for daratumumab

    Reuters – 7:36 AM ET 09/09/2015

    Genmab A/S (GNMSF). * Says Janssen has submitted a marketing authorization application to European Medicines Agency for daratumumab in double refractory multiple myeloma. * Says submission triggers a milestone payment of $10 million dollars to Genmab (GNMSF) from Janssen. * Says milestone was included in financial guidance for 2015 Source text for Eikon: Further company coverage:

  19. Show article details.

    How to make money in the coming economic 'ice age'

    MarketWatch – 8:58 AM ET 09/05/2015

    Analysts have a plan for investors to prosper during a sustained period of deflation in the U.S. Every day there are headlines about slowing economic growth in China, and the country's currency devaluation last month was a catalyst for painful volatility and declines of stocks worldwide. But these events may point to a longer-term problem that U.S. investors have to consider.

  20. Show article details.

    Johnson & Johnson to Participate in the 2015 Morgan Stanley Healthcare Conference

    PR Newswire – 9:00 AM ET 09/03/2015

    NEW BRUNSWICK, N.J., Sept. 3, 2015 Johnson & Johnson (JNJ) will participate in the 2015 Morgan Stanley Healthcare Conference on Thursday, Sept. 17, at the Grand Hyatt New York.


Today's and Upcoming Events

  • Oct

    JNJ to announce Q3 earnings Before Market (Confirmed)

  • Oct

    JNJ Earnings Conference Call at 8:30 AM Listen

Past Events (last 90 days)

  • Aug

    JNJ ex-Dividend for $0.75 on 8/21/2015

    • Announce Date: 7/20/2015
    • Record Date: 8/25/2015
    • Pay Date: 9/8/2015
Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.